The United States Food and Drug Administration has accepted the uniQure Huntington gene therapy application for Huntington’s disease. A decision is due by May 1, 2027. Reuters reports that the Dutch company announced the acceptance on Monday. It follows a long dispute with the regulator over the evidence.
The treatment is known as AMT-130, and also by the name ifezuntirgene inilparvovec. It is, in addition, a one time gene therapy designed to lower the abnormal huntingtin protein that drives Huntington’s disease. It is given directly into the brain, while it uses a microRNA that silences the faulty gene over time. Huntington’s disease slowly damages movement, thinking and mood.
No approved treatment today, however, changes the underlying course of Huntington’s disease in patients today. Current care eases symptoms, but it does not, meanwhile, slow the damage at its root. That gap explains, for example, why a gene therapy draws such close attention from families and doctors.
The uniQure Huntington gene therapy application rests on early to mid stage study results. Those results compare treated patients with an external Huntington’s disease database. The company has treated 51 patients across its studies so far. Its main evidence comes, in addition, from three year results in its Phase 1 and 2 programme.
That external comparison, rather than a randomised trial inside the application, sits at the heart of the dispute. Months before the acceptance, uniQure said AMT-130 had failed to slow disease progression in a four year trial. Its shares fell sharply on that news, and a senior FDA official had described the treatment as a failed product. The regulator later reversed course and agreed to review the application.

The FDA granted the uniQure Huntington gene therapy a faster review, and it is also considering a meeting of outside experts. The review runs under the accelerated approval pathway, which can allow speedier approval for serious diseases based on early evidence. That pathway requires later confirmation, and earlier access trades against a firm promise of proof. The confirmatory trial will stay under close watch throughout.
UniQure plans to begin screening patients in the United States by year end for a 200 patient follow up trial. Two thirds would receive the gene therapy, and the rest would instead receive standard care. The trial will measure total functional capacity at 36 months as its main endpoint. The company expects the uniQure Huntington gene therapy trial to be well under way by the time of any approval.
Screening will test whether families embrace a trial design that asks some patients to wait for standard care. The uniQure Huntington gene therapy story also raises a sharp ethical question that shaped the earlier dispute. The FDA had sought a randomised trial with a sham surgery control, while uniQure argued that brain surgery without benefit raised serious concerns. That clash touches how regulators judge rare disease treatments with small patient numbers.
If approved, the therapy would be described by the company as the opening disease modifying treatment for Huntington’s disease. That description is the company’s positioning, not an established fact. Accelerated approval rests on early evidence, so families should read the May 2027 decision as a milestone. It is not, thus, proof that the disease can now be stopped.

Shares in uniQure rose 2.5 percent in premarket trading on the uniQure Huntington gene therapy acceptance news. That modest move followed the sharp fall after the four year results. Investors will subsequently watch the advisory meeting decision. They will also watch enrolment in the confirmatory trial. A single acceptance letter rarely settles a scientific debate.
For patients and families, the message is patience mixed with hope, since no new treatment is available from this announcement alone. Doctors cannot offer AMT-130 outside a trial until the FDA acts, and the agency may still, however, ask hard questions at an expert meeting. The road from acceptance to approval is shorter, meanwhile, than the road from approval to proven benefit.
Huntington’s families have waited decades for a treatment that reaches the cause of the disease rather than only its symptoms. This uniQure Huntington gene therapy application brings that hope one step closer to a formal verdict, while the evidence still faces honest scrutiny. Gene editing in a mouse brain shows how delivery science is advancing, but human proof still takes time.
